Molecular Partners Ag (MOLN) Change in Account Payables (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Change in Account Payables of $192.83 for Q1 2026, down 75.09% year-over-year from $774.13 in Q1 2025, and down 99.76% quarter-over-quarter from $80794.3 in Q4 2025.
Molecular Partners Ag (MOLN) Change in Account Payables (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Change in Account Payables for 7 consecutive years, with $192.83 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables fell 75.09% year-over-year to $192.83; the TTM figure through Mar 2026 stood at $69236.3 (down 86.74% YoY), while the FY2025 annual figure was $81326.0, down 86.4% from the prior year.
- Change in Account Payables eased to $192.83 in Q1 2026 per MOLN's latest filing, from $80794.3 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.9 million in Q3 2022 and bottomed at -$5.5 million in Q4 2022.
- Historically, Change in Account Payables has averaged -$345940.2 across 5 years, with a median of $773.03 in 2023.
- Annual changes were most pronounced in 2022 — Change in Account Payables slumped 407.97% — and 2024, when it jumped 174.63%.
- Molecular Partners Ag's Change in Account Payables stood at -$5.5 million in 2022, then soared by 83.47% to -$915352.1 in 2023, then surged by 165.22% to $596955.4 in 2024, then plunged by 86.47% to $80794.3 in 2025, then sank by 99.76% to $192.83 in 2026.
- Business Quant data shows MOLN's Change in Account Payables at $192.83 in Q1 2026, $80794.3 in Q4 2025, and -$338248.4 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | 192.83 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 192.83 |
| Mar 31, 2026 | 192.83 |
| Dec 31, 2025 | 80,794.29 |
| Dec 31, 2025 | 80,794.29 |
| Sep 30, 2025 | -338,248.38 |
| Sep 30, 2025 | -338,248.38 |
| Jun 30, 2025 | 326,497.56 |
| Jun 30, 2025 | 326,497.56 |
| Mar 31, 2025 | 774.13 |
| Mar 31, 2025 | 774.13 |
| Dec 31, 2024 | 596,955.43 |
| Dec 31, 2024 | 596,955.43 |
| Sep 30, 2024 | -1.78 Mn |
| Sep 30, 2024 | -1.78 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Mar 31, 2024 | 2,122.95 |
| Mar 31, 2024 | 2,122.95 |
| Dec 31, 2023 | -915,352.08 |
| Dec 31, 2023 | -915,352.08 |